Lactams

10/26/2022 - "Our work demonstrates that L-form switching is an effective adaptive strategy in stressful environments and can be expected to limit the efficacy of β-lactam for many important infections."
01/01/2023 - "Despite the global high prevalence of group A Streptococcus (GAS) infections and the global widespread use of β-lactams, β-lactams remain the first-line treatment option for GAS infection. "
12/01/2012 - "In summary, our data show that the DAP-β-lactam combination may significantly enhance both the in vitro and in vivo efficacy of anti-MRSA therapeutic options against DAP(r) MRSA infections and represent an option in preventing DAP(r) selection in persistent or refractory MRSA infections."
09/01/2022 - "Currently, no single agent can treat all MDR-GNB infections, but new β-lactam-β-lactamase inhibitor combinations are often effective for different infection sites and, when used appropriately, have the potential to improve outcomes. "
01/01/2020 - "First-line β-lactams of lower generations can be used effectively against MRSA infection when used in combination. "

01/01/2017 - "Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)."
12/01/2015 - "A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis."
09/01/2015 - "The aim of this study was to assess the pharmacokinetic and pharmacodynamic target attainment of intravenous β-lactam regimens commonly used to treat bloodstream infections (BSIs) caused by Gram-negative rod-shaped organisms in a Brazilian teaching hospital. "
01/01/2023 - "Optimal β-lactam dosing for the treatment of Gram-negative bacteria bloodstream infections (GNB-BSIs) remains a debated issue. "
01/01/2023 - "Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study."

09/01/2021 - "Through PAC and the BLAA protocol, 86 patients (31%) were cleared for allergy removal, and 188 (68%) were cleared for alternative β-lactams. "
03/22/2022 - "In this study, we evaluated a standardized algorithm aiming to differentiate non-allergic patients from those with true allergic β-lactam hypersensitivity. "
01/01/2022 - "This study confirms that patients with declared β-lactam allergy had not a higher risk of ESBL bacterial acquisition during hospitalization in ICU. "
01/01/2022 - "In a previous study conducted over a 6-year long period (2007-2012), we found that patients with declared β-lactam allergy had a higher risk of ESBL bacterial carriage at admission in intensive care unit (ICU), but they had not a higher risk of ESBL bacterial acquisition. "
01/01/2021 - "Particular patterns of allergy-test positivity observed in some studies that assessed cross-reactivity among β-lactams seem to indicate that prior exposures may be responsible for coexisting sensitivities. "

01/01/2020 - "Efficacy of Early Oral Switch with β-Lactams for Low-Risk Staphylococcus aureus Bacteremia."
02/15/2022 - "The aim of this study was to characterize 256 β-lactam-resistant, bacteremia-causing E. "
11/01/2023 - "Recent data evaluating use of dual β-lactam regimens for persistent MSSA bacteremia were limited to 8 case reports or case series. "
01/01/2022 - "Although literature to support extended infusion β-lactams exists for adults, few data are available in pediatrics, especially among patients with bacteremia. "
01/01/2022 - "Extended Infusion β-Lactams for the Treatment of Gram-Negative Bacteremia in Children."

10/01/2018 - "Administration of β-lactams by extended infusion strategies improves the rate of this pharmacodynamic target attainment and has been associated with improved outcomes in several randomized trials in critically-ill patients. "
12/01/2020 - "β-Lactam antimicrobial  pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study."
10/01/2020 - "The objective of this study was to compare the incidence of AKI associated with the use of PT to other β-lactams among adult critically ill patients METHODS: This retrospective study was conducted in the surgical and the medical intensive care units at two hospitals within Hamad Medical Corporation (HMC) in Qatar and included adult critically ill patients who received at least one dose of anti-pseudomonal β-lactams. "
07/01/2016 - "The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France."
06/23/2014 - "The goal of this study was to evaluate if and why serum concentrations are inadequate when standard β-lactam regimens are administered to obese, non-critically ill patients. "